-
Je něco špatně v tomto záznamu ?
GAD antibodies in T1D and LADA--relations to age, BMI, c-peptide, IA-2 and HLA-DRB1*03 and DRB1*04 alleles
P. Weber, P. Ambrosova, P. Canov, D. Weberova, P. Kuklinek, H. Meluzinova, H. Matejovska-Kubesova, P. Cejkova, K. Bielakova, M. Cerna,
Jazyk angličtina Země Rusko
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 2011-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2011-01-01 do Před 1 rokem
PubMed
21957594
Knihovny.cz E-zdroje
- MeSH
- alely MeSH
- autoprotilátky krev MeSH
- C-peptid krev MeSH
- diabetes mellitus 1. typu krev genetika imunologie MeSH
- dospělí MeSH
- glutamát dekarboxyláza imunologie MeSH
- HLA-DR antigeny genetika MeSH
- HLA-DRB1 řetězec MeSH
- index tělesné hmotnosti MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- tyrosinfosfatasy receptorového typu, třída 8 imunologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
The determination of GADA may be useful for clinical classification of diabetes mellitus (DM) in clinically unclear cases. This GADA positivity may persist in any diabetics Type 1 Diabetes Mellitus (T1D) with an onset in adulthood and Late Autoimmune Diabetes of Adults (LADA) many years after appearance of DM. The study was aimed at comparing the levels of GADA between both diabetic subsets with their clinical parameters, age of onset DM, period of insulin need, body mass index, HbA1C, fasting and postprandial C-peptide, risky HLA-DRB1* alleles, occurrence of micro- and macrovascular diabetic complications. Further analysis of GADA titers in different time consequences to the development of DM and relations to IA-2 were made. In the study, we included 130 diabetics with an onset of diabetes (T1D or LADA) 35+ y. who were hospitalized and afterwards long-term observed in the diabetological outpatient department. Out of this number there were 62 men and 68 women of the average age 65.5 +/- 14.0 y. (range 35-93 y.). 54 were assessed as the T1D patients and 76 as the LADA ones. Patients of the T1D subgroup were GADA positive 22 times and of the LADA subgroup 21 times. LADA 2 patients that were GADA negative were more obese than GADA positive LADA diabetics (p < 0.01). Also postprandial C-peptide was higher in LADA patients GADA negative (p < 0.05). Other clinical characteristics were without statistically significant differences. We found in our diabetic patients a relation between alleles HLA-DRB1*03 and particularly combination with HLA-DRB1*04 with positive GADA levels. In the GADA negative group obesity, coronary heart disease, hypertension, syndrome of diabetic foot and dyslipidaemia appeared more frequently (OR = 2.8; 3.1; 6.2 and 2.4). We found no significant differences in observed parameters--comparison GADA positivity and negativity according to the duration of DM. GADA positive were even 10 y. duration 16 times and after 20 y. even 6 times. Recent DM had positive GADA in 11 cases and 13 cases of recent DM had GADA negative. IA-2 antibodies were positive (> 1.0 U/ml) 18 times altogether and always with positive GADA, but only 7 times in recent DM. The presence of elevated GADA identifies patients unequivocally suitable for early insulin therapy. Our observations and experiences confirm that GADA can be found increased after more than 10-20 years duration of DM, although in decreasing trend.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12028034
- 003
- CZ-PrNML
- 005
- 20200318175549.0
- 007
- ta
- 008
- 120817s2011 ru f 000 0#eng||
- 009
- AR
- 035 __
- $a (PubMed)21957594
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ru
- 100 1_
- $a Weber, Pavel $7 xx0102175 $u Department of Internal Medicine, Geriatrics and Practical Medicine, Faculty Hospital and Masaryk University, Brno, Czech Republic. p.weber@fnbrno.cz
- 245 10
- $a GAD antibodies in T1D and LADA--relations to age, BMI, c-peptide, IA-2 and HLA-DRB1*03 and DRB1*04 alleles / $c P. Weber, P. Ambrosova, P. Canov, D. Weberova, P. Kuklinek, H. Meluzinova, H. Matejovska-Kubesova, P. Cejkova, K. Bielakova, M. Cerna,
- 520 9_
- $a The determination of GADA may be useful for clinical classification of diabetes mellitus (DM) in clinically unclear cases. This GADA positivity may persist in any diabetics Type 1 Diabetes Mellitus (T1D) with an onset in adulthood and Late Autoimmune Diabetes of Adults (LADA) many years after appearance of DM. The study was aimed at comparing the levels of GADA between both diabetic subsets with their clinical parameters, age of onset DM, period of insulin need, body mass index, HbA1C, fasting and postprandial C-peptide, risky HLA-DRB1* alleles, occurrence of micro- and macrovascular diabetic complications. Further analysis of GADA titers in different time consequences to the development of DM and relations to IA-2 were made. In the study, we included 130 diabetics with an onset of diabetes (T1D or LADA) 35+ y. who were hospitalized and afterwards long-term observed in the diabetological outpatient department. Out of this number there were 62 men and 68 women of the average age 65.5 +/- 14.0 y. (range 35-93 y.). 54 were assessed as the T1D patients and 76 as the LADA ones. Patients of the T1D subgroup were GADA positive 22 times and of the LADA subgroup 21 times. LADA 2 patients that were GADA negative were more obese than GADA positive LADA diabetics (p < 0.01). Also postprandial C-peptide was higher in LADA patients GADA negative (p < 0.05). Other clinical characteristics were without statistically significant differences. We found in our diabetic patients a relation between alleles HLA-DRB1*03 and particularly combination with HLA-DRB1*04 with positive GADA levels. In the GADA negative group obesity, coronary heart disease, hypertension, syndrome of diabetic foot and dyslipidaemia appeared more frequently (OR = 2.8; 3.1; 6.2 and 2.4). We found no significant differences in observed parameters--comparison GADA positivity and negativity according to the duration of DM. GADA positive were even 10 y. duration 16 times and after 20 y. even 6 times. Recent DM had positive GADA in 11 cases and 13 cases of recent DM had GADA negative. IA-2 antibodies were positive (> 1.0 U/ml) 18 times altogether and always with positive GADA, but only 7 times in recent DM. The presence of elevated GADA identifies patients unequivocally suitable for early insulin therapy. Our observations and experiences confirm that GADA can be found increased after more than 10-20 years duration of DM, although in decreasing trend.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a alely $7 D000483
- 650 _2
- $a autoprotilátky $x krev $7 D001323
- 650 _2
- $a index tělesné hmotnosti $7 D015992
- 650 _2
- $a C-peptid $x krev $7 D002096
- 650 _2
- $a diabetes mellitus 1. typu $x krev $x genetika $x imunologie $7 D003922
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glutamát dekarboxyláza $x imunologie $7 D005968
- 650 _2
- $a HLA-DR antigeny $x genetika $7 D006684
- 650 _2
- $a HLA-DRB1 řetězec $7 D059811
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a tyrosinfosfatasy receptorového typu, třída 8 $x imunologie $7 D054635
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ambrosova, P $7 gn_A_00005378
- 700 1_
- $a Canov, P
- 700 1_
- $a Prudius, Dana $7 xx0231152
- 700 1_
- $a Kuklínek, Pavel $7 xx0000490
- 700 1_
- $a Meluzínová, Hana $7 xx0062326
- 700 1_
- $a Matějovská Kubešová, Hana, $d 1957- $7 nlk20000083650
- 700 1_
- $a Čejková, P
- 700 1#
- $a Bielaková, Katarína. $7 xx0230571
- 700 1_
- $a Černá, M
- 773 0_
- $w MED00179769 $t Advances in gerontology Uspekhi gerontologii Rossiĭskai͡a akademii͡a nauk, Gerontologicheskoe obshchestvo $x 1561-9125 $g Roč. 24, č. 2 (2011), s. 312-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21957594 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20200318180013 $b ABA008
- 999 __
- $a ok $b bmc $g 950076 $s 785380
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 24 $c 2 $d 312-8 $i 1561-9125 $m Advances in gerontology $n Adv Gerontol $x MED00179769
- LZP __
- $a Pubmed-20120817/11/04